Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Clinical trial NCT05226598 · COMPLETED
Trial details
- NCT number
- NCT05226598
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-24
- Primary completion
- 2024-09-24
- Enrollment
- 739
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.